Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/239622
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Active psychosis and pro-inflammatory cytokines in first-episode of psychosis |
Autor: | Pardo-de-Santayana, Guillermo; Juncal Ruiz, María; Vázquez-Bourgon, Javier; Riesco-Dávila, Laura; Ortiz-Garcia de la Foz, Victor; Pelayo-Terán, José María; López-Hoyos, Marcos; Crespo-Facorro, Benedicto CSIC ORCID CVN | Palabras clave: | Schizophrenia Psychosis Low-grade inflammation Cytokines Chemokines Neurotoxicity hypothesis |
Fecha de publicación: | feb-2021 | Editor: | Elsevier | Citación: | Journal of Psychiatric Research 134: 150-157 (2021) | Resumen: | Higher levels of pro-inflammatory cytokines are consistently found in the serum of first episode psychosis (FEP) patients and this immune dysfunction could contribute to neural harm. On the other hand, lengthy periods of active psychosis during the early phases of the illness appear to be associated to worst functional outcome. We aim to explore the possible relationship between lengthy periods of active psychosis during early phases of the illness and the levels of pro-inflammatory cytokines. This is a prospective clinical study consisting of a 3-year clinical follow-up. We assessed the relation between the duration of active psychosis in patients with FEP and the serum levels of 21 cytokines at baseline and 3 months after initiating antipsychotic medication. We used the Human High Sensitivity T Cell Magnetic Bead Panel protocol from the Milliplex® Map Kit. The sample consisted of 59 patients with a FEP. The percentage of variation of the serum levels of the chemokine MIP-3α during the first 3 months of antipsychotic treatment and the score in negative psychotic symptoms 3 months after the initiation of antipsychotic medication, acted as predictors of the initial time to remission of positive psychotic symptoms. Our findings open the possibility to investigating the potential use of the variation in chemokine MIP-3α serum levels during the first months of antipsychotic treatment to identify a subtype of FEP patients that could benefit from an add-on treatment with immune modulators. | Versión del editor: | http://doi.org/10.1016/j.jpsychires.2020.12.060 | URI: | http://hdl.handle.net/10261/239622 | DOI: | 10.1016/j.jpsychires.2020.12.060 | Identificadores: | doi: 10.1016/j.jpsychires.2020.12.060 issn: 0022-3956 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
6
checked on 28-mar-2024
WEB OF SCIENCETM
Citations
5
checked on 25-feb-2024
Page view(s)
62
checked on 18-abr-2024
Download(s)
15
checked on 18-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.